Dubious — cellular senescence (whether proliferation- or oncogene-induced) is the usual failsafe for avoiding proliferation of damaged cells. It relies heavily upon TP53, RB1, and CDKN2A, all of which are routinely deleted in tumors. When anti-aging researchers refer to senolytic drugs, usually they’re referring to drugs that clear senescent cells.
Oddly, the drugs tend to clear out tumor cells in many cases, as senescence bypass is a critical step in carcinogenesis.
Not oddly, the inflammatory paracrine (secreted) profile of senescent cells tends to engage the immune system in clearing them out. Immunosenescence gets in the way of this and also of clearing precancerous cells, hence it is a risk factor for both age-related frailty and cancer.
Oddly, the drugs tend to clear out tumor cells in many cases, as senescence bypass is a critical step in carcinogenesis.
Not oddly, the inflammatory paracrine (secreted) profile of senescent cells tends to engage the immune system in clearing them out. Immunosenescence gets in the way of this and also of clearing precancerous cells, hence it is a risk factor for both age-related frailty and cancer.